Biologic Insulin Gets FDA Tentative Approval
July 24th 2017The FDA has granted tentative approval to Merck's Lusduna Nexvue (insulin glargine injection) 100 units/mL. The drug is a follow-on biologic basal insulin for patients with type 2 diabetes and is administered through a pre-filled dosing device, according to a press release.
Read More